Syndax Pharmaceuticals Inc (SNDX) Shares Up Despite Recent Market Volatility

Syndax Pharmaceuticals Inc (NASDAQ: SNDX)’s stock price has plunge by 2.15relation to previous closing price of 23.29. Nevertheless, the company has seen a 10.96% surge in its stock price over the last five trading sessions. CNBC Television reported 2024-04-03 that Michelle Ross, StemPoint Capital CIO, joins CNBC’s Halftime Report’ to discuss her latest biotech pick.

Is It Worth Investing in Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Right Now?

Moreover, the 36-month beta value for SNDX is 0.98. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

The public float for SNDX is 80.62M and currently, short sellers hold a 10.33% of that float. On April 04, 2024, SNDX’s average trading volume was 1.21M shares.

SNDX’s Market Performance

SNDX stock saw an increase of 10.96% in the past week, with a monthly gain of 2.10% and a quarterly increase of 8.83%. The volatility ratio for the week is 5.70%, and the volatility levels for the last 30 days are 5.02% for Syndax Pharmaceuticals Inc (SNDX). The simple moving average for the past 20 days is 2.87% for SNDX’s stock, with a 25.21% simple moving average for the past 200 days.

Analysts’ Opinion of SNDX

Many brokerage firms have already submitted their reports for SNDX stocks, with Scotiabank repeating the rating for SNDX by listing it as a “Sector Perform.” The predicted price for SNDX in the upcoming period, according to Scotiabank is $23 based on the research report published on January 31, 2024 of the current year 2024.

Mizuho, on the other hand, stated in their research note that they expect to see SNDX reach a price target of $45. The rating they have provided for SNDX stocks is “Buy” according to the report published on December 22nd, 2023.

BofA Securities gave a rating of “Buy” to SNDX, setting the target price at $29 in the report published on October 25th of the previous year.

SNDX Trading at 5.87% from the 50-Day Moving Average

After a stumble in the market that brought SNDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.12% of loss for the given period.

Volatility was left at 5.02%, however, over the last 30 days, the volatility rate increased by 5.70%, as shares surge +3.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.10% upper at present.

During the last 5 trading sessions, SNDX rose by +10.96%, which changed the moving average for the period of 200-days by +11.53% in comparison to the 20-day moving average, which settled at $23.17. In addition, Syndax Pharmaceuticals Inc saw 10.09% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at SNDX starting from Morrison Briggs, who sale 52,855 shares at the price of $18.27 back on Aug 09 ’23. After this action, Morrison Briggs now owns 17,836 shares of Syndax Pharmaceuticals Inc, valued at $965,402 using the latest closing price.

Meury William, the Director of Syndax Pharmaceuticals Inc, sale 83,000 shares at $20.46 during a trade that took place back on Aug 02 ’23, which means that Meury William is holding 48,000 shares at $1,697,810 based on the most recent closing price.

Stock Fundamentals for SNDX

Current profitability levels for the company are sitting at:

  • -429.02 for the present operating margin

The net margin for Syndax Pharmaceuticals Inc stands at -381.4. The total capital return value is set at -0.41. Equity return is now at value -40.98, with -37.72 for asset returns.

Based on Syndax Pharmaceuticals Inc (SNDX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -98.23. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -3381.66.

Currently, EBITDA for the company is -229.94 million with net debt to EBITDA at 1.34. When we switch over and look at the enterprise to sales, we see a ratio of 3223.08. The receivables turnover for the company is 0.44for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.00.

Conclusion

To wrap up, the performance of Syndax Pharmaceuticals Inc (SNDX) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.

Related Posts